Advertisement
|
|
|
|
|
Free Trial
Description: Elchanan Bruckheimer is Rafael Medical Technologies Dir Medical. With a Lead411 subscription, Rafael Medical Technologies email addresses ( @rafaelmedical.com ) of the executives are viewable. Other information includes Elchanan Bruckheimer email, phone, and extension.
Be sure to check our Linkedin tab on the company page. Typical management titles include VP, Chief, Vice President, Director, manager, & more. Similar names to Bruckheimer can be found at Executive Directory - Bruckheimer.
|
Add Elchanan Bruckheimer Information
Site Reference: http://www.rafaelmedical.com/publications.html#pub_01
Elchanan Bruckheimer Hamish Ireland, Johannes Lammer, Thomas Rand, Peter Nathaniel. ABSTRACT - BSIR 2004 SafeFloŽ Retrievable Inferior Vena Cava Filter: An Open, Multicenter Study J. Lammer, P. Nathaniel, J. Kettenbach, M. Schoder, T. Rand, I. von Katzler, B. Katzen, E. Bruckheimer. ABSTRACT - CIRCE 2004 In Vitro Evaluation of a Retrievable Low-Profile Nitinol Vena Cava Filter JVasc Interv Radiol 2003 14: 469-474. Elchanan Bruckheimer, Alon G. Judelman, Simon D. Bruckheimer, Isaac Tavori, Gil Naor, and Barry T. Katzen ABSTRACT ( http://www.jvir.org/cgi/content/abstract/14/4/469 ) In Vitro and In Vivo Evaluation of SafeFloŽ, a New Retrievable IVC Filter. E. Bruckheimer, A. Judelman, G. Naor, B.T. Katzen. ABSTRACT - ISET 2003 In Vivo Evaluation of the SafeFloŽ Retrievable Inferior Vena Cava Filter. E. Bruckheimer, A. Judelman, G. Naor, B.T. Katzen. ABSTRACT - SIR 2003 Multicentre experience with the new SafeFloŽ retrievable nitinol caval filter. Dr Kieran McBride, Queen Margaret Rafael Medical Technologies, Cesarea, Israel ABSTRACT - CIRSE - 2005 Purpose : To demonstrate the safety and effectiveness of a novel hookless retrievable nitinol inferior vena cava filter. Materials and Methods : Over 19 months, 40 SafeFloŽ (Rafael Medical Technologies) filters were placed in 40 patients [20 male; age range 27 to 83 (average 59 years)], at 4 centres. Indications included standard criteria and also prophylactic placement in pre-operative high-risk surgical patients. The device was inserted transjugular in 22 and transfemoral in 18 cases. Back to Top In Vitro and In Vivo Evaluation of SafeFloŽ, a New Retrievable IVC Filter. E. Bruckheimer, A. Judelman, G. Naor, B.T. Katzen. ABSTRACT - ISET 2003 Background : The SafeFloŽ IVC filter is retrievable IVC filter, consists of a double-ring platform and a two-wire spiral and employs a 5Fr delivery catheter. Purpose : To evaluate the implantation, clot trapping ability, migration, vessel response Hamish Ireland, Johannes Lammer, Thomas Rand, Peter Nathaniel. Departments of Radiology, Queen Margaret Hospital, Dunfermline, Royal Infirmary of Edinburgh Scotland, Medical University Vienna, Austria, University Hospital Bloemfontein, South Africa and RMT Medical Technologies, Ltd., Caesarea, Israel. Purpose: To evaluate safety, retrievability and effectiveness of the SafeFloŽ IVC filter in an IRB approved clinical trial of filter implantation to prevent pulmonary embolism [PE]. Materials and Methods: The nitinol filter has a hookless double-ring for fixation and a spiral filter element. Delivery employs a 6F sheath via jugular or femoral vein. Retrieval is performed with a multi-loop snare through a 7F sheath. In-vitro and in-vivo testing demonstrated satisfactory clot- trapping [90.7%], stability and no migration when oversized with retrievability up to 30 days. Back to Top
|
|
| Copyright 2010 Lead411 | Santa Barbara, CA |
|
|
|
|
Advertisement
|
